These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 37452456)

  • 1. The "Begin Exploring Fertility Options, Risks and Expectations" (BEFORE) decision aid: development and alpha testing of a fertility tool for premenopausal breast cancer patients.
    Speller B; Metcalfe K; Kennedy ED; Facey M; Greenblatt E; Scheer AS; Warner E; Joy AA; Wright FC; Baxter NN
    BMC Med Inform Decis Mak; 2019 Oct; 19(1):203. PubMed ID: 31660965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis.
    Zisman-Ilani Y; Shern D; Deegan P; Kreyenbuhl J; Dixon L; Drake R; Torrey W; Mishra M; Gorbenko K; Elwyn G
    BMC Psychiatry; 2018 May; 18(1):142. PubMed ID: 29788933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series.
    Mølgaard SN; Nielsen MØ; Roed K; Nielsen J
    BMC Psychiatry; 2024 Mar; 24(1):240. PubMed ID: 38553687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an Electronic Decision Aid Tool to Facilitate Mainstream Genetic Testing in Ovarian Cancer Patients.
    Shannon KM; Patel D; Jonas JM; Blouch EL; Hicks SR; Wooters M; Seidel M; Grant CF; Emmet MM; Chung DC; Sepucha K
    Oncologist; 2024 May; 29(5):e665-e671. PubMed ID: 38297990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Decision Aid for Chemotherapy or Exclusion in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer: Development, Alpha Testing, and Peer Validation.
    Bacorro W; Baldivia K; Mariano J; Dancel E; Antonio L; Gonzalez G; Ortin TS; Canlas R
    JCO Glob Oncol; 2023 Sep; 9():e2300096. PubMed ID: 37677124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shared Decision Making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatment.
    Leucht S; Siafis S; Rodolico A; Peter NL; Müller K; Waibel J; Strube W; Hasan A; Bauer I; Brieger P; Davis JM; Hamann J
    Eur Arch Psychiatry Clin Neurosci; 2023 Dec; 273(8):1629-1631. PubMed ID: 38017193
    [No Abstract]   [Full Text] [Related]  

  • 7. Usability and Feasibility of the Antipsychotic Medication Decision Aid in a Community Program for First-Episode Psychosis.
    Zisman-Ilani Y; Parker M; Thomas EC; Suarez J; Hurford I; Bowen A; Calkins M; Deegan P; Nossel I; Dixon LB
    Psychiatr Serv; 2024 Mar; ():appips20230230. PubMed ID: 38477836
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Naguy A; Pridmore S; Alamiri B
    Psychopharmacol Bull; 2023 Feb; 53(1):55-57. PubMed ID: 36873922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
    Siafis S; Wu H; Wang D; Burschinski A; Nomura N; Takeuchi H; Schneider-Thoma J; Davis JM; Leucht S
    Mol Psychiatry; 2023 Aug; 28(8):3267-3277. PubMed ID: 37537284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.
    Meyer JM; Correll CU
    CNS Drugs; 2023 Jul; 37(7):545-570. PubMed ID: 37470979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity-Dependent Transcriptional Program in NGN2+ Neurons Enriched for Genetic Risk for Brain-Related Disorders.
    Ma Y; Bendl J; Hartley BJ; Fullard JF; Abdelaal R; Ho SM; Kosoy R; Gochman P; Rapoport J; Hoffman GE; Brennand KJ; Roussos P
    Biol Psychiatry; 2024 Jan; 95(2):187-198. PubMed ID: 37454787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of hypertension, type 2 diabetes mellitus and dyslipidemia with the duration of inpatient treatments and recurrence of schizophrenia.
    Lamadé EK; Özer N; Schaupp B; Krumm B; Deuschle M; Häfner S
    J Psychosom Res; 2023 Sep; 172():111436. PubMed ID: 37454415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One hundred and fifty years of hebephrenia. A review.
    Martínez DR
    Rev Colomb Psiquiatr (Engl Ed); 2023; 52(2):139-145. PubMed ID: 37453821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia.
    Aoki Y; Takaesu Y; Matsui K; Tokumasu T; Tani H; Takekita Y; Kanazawa T; Kishimoto T; Tarutani S; Hashimoto N; Takeuchi H; Mishima K; Inada K
    Neuropsychopharmacol Rep; 2023 Sep; 43(3):391-402. PubMed ID: 37452456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision aid development and its acceptability among adults with attention-deficit/hyperactivity disorders regarding treatment discontinuation after remission.
    Tsujii N; Okada T; Usami M; Kuwabara H; Fujita J; Negoro H; Iida J; Aoki Y; Takaesu Y; Saito T
    PCN Rep; 2022 Dec; 1(4):e57. PubMed ID: 38868662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission.
    Aoki Y; Takaesu Y; Baba H; Iga JI; Hori H; Inoue T; Mishima K; Tajika A; Kato M
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):306-314. PubMed ID: 35775506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.
    Aoki Y; Takaesu Y; Suzuki M; Okajima I; Takeshima M; Shimura A; Utsumi T; Kotorii N; Yamashita H; Kuriyama K; Watanabe N; Mishima K
    Neuropsychopharmacol Rep; 2022 Mar; 42(1):10-20. PubMed ID: 34807524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.
    Aoki Y; Takaesu Y; Inada K; Yamada H; Murao T; Kikuchi T; Takeshima M; Tani M; Mishima K; Otsubo T
    Front Psychiatry; 2023; 14():1083568. PubMed ID: 37252154
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.